These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 25338975)

  • 21. Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled study.
    Levy HL; Milanowski A; Chakrapani A; Cleary M; Lee P; Trefz FK; Whitley CB; Feillet F; Feigenbaum AS; Bebchuk JD; Christ-Schmidt H; Dorenbaum A;
    Lancet; 2007 Aug; 370(9586):504-10. PubMed ID: 17693179
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term preservation of intellectual functioning in sapropterin-treated infants and young children with phenylketonuria: A seven-year analysis.
    Waisbren S; Burton BK; Feigenbaum A; Konczal LL; Lilienstein J; McCandless SE; Rowell R; Sanchez-Valle A; Whitehall KB; Longo N
    Mol Genet Metab; 2021 Feb; 132(2):119-127. PubMed ID: 33485801
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of sapropterin dihydrochloride in increasing phenylalanine tolerance in children with phenylketonuria: a phase III, randomized, double-blind, placebo-controlled study.
    Trefz FK; Burton BK; Longo N; Casanova MM; Gruskin DJ; Dorenbaum A; Kakkis ED; Crombez EA; Grange DK; Harmatz P; Lipson MH; Milanowski A; Randolph LM; Vockley J; Whitley CB; Wolff JA; Bebchuk J; Christ-Schmidt H; Hennermann JB;
    J Pediatr; 2009 May; 154(5):700-7. PubMed ID: 19261295
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Response of patients with phenylketonuria in the US to tetrahydrobiopterin.
    Matalon R; Michals-Matalon K; Koch R; Grady J; Tyring S; Stevens RC
    Mol Genet Metab; 2005 Dec; 86 Suppl 1():S17-21. PubMed ID: 16143554
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Open, non-comparative phase III clinical study to evaluate the efficacy and safety of sapropterin in patients with phenylketonuria and hyperphenylalaninemia].
    Bushueva TV; Kuzenkova LM; Borovik TÉ; Nazarenko LP; Seitova GN; Filimonova MN; Pichkur NA; Samonenko NV; Shkurko TA; Akhmadeeva ÉN; Mardanova AK; Garifullina ÉR; Kovtun OP; Bazhenova IuL; Alimova IL; Kostiakova EA; Minaĭcheva LI; Saliukova OA; Sivokha VM; Rozenson OL
    Vestn Ross Akad Med Nauk; 2014; (7-8):69-77. PubMed ID: 25563006
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term comparative effectiveness of pegvaliase versus standard of care comparators in adults with phenylketonuria.
    Zori R; Ahring K; Burton B; Pastores GM; Rutsch F; Jha A; Jurecki E; Rowell R; Harding C
    Mol Genet Metab; 2019; 128(1-2):92-101. PubMed ID: 31439512
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sapropterin dihydrochloride for phenylketonuria.
    Somaraju UR; Merrin M
    Cochrane Database Syst Rev; 2015 Mar; 2015(3):CD008005. PubMed ID: 25812600
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Individualized long-term outcomes in blood phenylalanine concentrations and dietary phenylalanine tolerance in 11 patients with primary phenylalanine hydroxylase (PAH) deficiency treated with Sapropterin-dihydrochloride.
    Stockler-Ipsiroglu S; Yuskiv N; Salvarinova R; Apatean D; Ho G; Cheng B; Giezen A; Lillquist Y; Ueda K
    Mol Genet Metab; 2015 Mar; 114(3):409-14. PubMed ID: 25497838
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Longitudinal quality of life analysis in a phenylketonuria cohort provided sapropterin dihydrochloride.
    Douglas TD; Ramakrishnan U; Kable JA; Singh RH
    Health Qual Life Outcomes; 2013 Dec; 11():218. PubMed ID: 24373161
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Response to sapropterin hydrochloride (Kuvan®) in children with phenylketonuria (PKU): a clinical trial.
    Eshraghi P; Noroozi Asl S; Bagheri S; Chalak V
    J Pediatr Endocrinol Metab; 2019 Aug; 32(8):885-888. PubMed ID: 31237861
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relative bioavailability of sapropterin from intact and dissolved sapropterin dihydrochloride tablets and the effects of food: a randomized, open-label, crossover study in healthy adults.
    Musson DG; Kramer WG; Foehr ED; Bieberdorf FA; Hornfeldt CS; Kim SS; Dorenbaum A
    Clin Ther; 2010 Feb; 32(2):338-46. PubMed ID: 20206791
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sapropterin dihydrochloride, 6-R-L-erythro-5,6,7,8-tetrahydrobiopterin, in the treatment of phenylketonuria.
    Michals-Matalon K
    Expert Opin Investig Drugs; 2008 Feb; 17(2):245-51. PubMed ID: 18230057
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adherence to tetrahydrobiopterin therapy in patients with phenylketonuria.
    Rohr F; Wessel A; Brown M; Charette K; Levy HL
    Mol Genet Metab; 2015 Jan; 114(1):25-8. PubMed ID: 25467057
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimizing the use of sapropterin (BH(4)) in the management of phenylketonuria.
    Blau N; Bélanger-Quintana A; Demirkol M; Feillet F; Giovannini M; MacDonald A; Trefz FK; van Spronsen FJ
    Mol Genet Metab; 2009 Apr; 96(4):158-63. PubMed ID: 19208488
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sapropterin dihydrochloride for phenylketonuria.
    Somaraju UR; Merrin M
    Cochrane Database Syst Rev; 2012 Dec; 12():CD008005. PubMed ID: 23235653
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Spotlight on sapropterin in primary hyperphenylalaninemia.
    Sanford M; Keating GM
    BioDrugs; 2009; 23(3):201-2. PubMed ID: 19627172
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sapropterin dihydrochloride (Kuvan/phenoptin), an orally active synthetic form of BH4 for the treatment of phenylketonuria.
    Burnett JR
    IDrugs; 2007 Nov; 10(11):805-13. PubMed ID: 17968763
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sapropterin dihydrochloride for phenylketonuria.
    Somaraju UR; Merrin M
    Cochrane Database Syst Rev; 2010 Jun; (6):CD008005. PubMed ID: 20556789
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sapropterin dihydrochloride for phenylketonuria and tetrahydrobiopterin deficiency.
    Blau N
    Expert Rev Endocrinol Metab; 2010 Jul; 5(4):483-494. PubMed ID: 30780801
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sapropterin therapy increases stability of blood phenylalanine levels in patients with BH4-responsive phenylketonuria (PKU).
    Burton BK; Bausell H; Katz R; Laduca H; Sullivan C
    Mol Genet Metab; 2010; 101(2-3):110-4. PubMed ID: 20638313
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.